U-Blot® Research Grade Polatuzumab

Name: U-Blot® Research Grade Polatuzumab
SKU: WA3373
Availability: InStock

$9,999.00

Size:50ug

SKU: WA3373-50

Catalog No.: WA3373

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

Product details Specifications Q & A Education

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.: WA3373
SKU: WA3373-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: CD79B
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Humanized
Isotype: IgG1-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% purity as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: B-cell-specific glycoprotein B29, CD79B, B-cell antigen receptor complex-associated protein beta chain, Ig-beta, B29, Immunoglobulin-associated B29 protein, IGB, CD79b
Species: --
Gene ID-1: P40259
Uniprot: --
Background: Polatuzumab vedotin is an antibody-drug conjugate formed by a CD79b antibody conjugated to the highly cytotoxic agent monomethyl auristatin E by means of a cleavable linker. Following significant clinical efficacy in R/R DLBCL, polatuzumab vedotin was granted accelerated Food and Drug Administration (FDA) approval in combination with bendamustine plus rituximab for patients who have failed at least two prior therapies. Other clinical studies involving polatuzumab vedotin in combination with other therapy regimens are also under evaluation for previously untreated DLBCL patients.<br>
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.